Research peptide
TB-500 + BPC-157
Batch analytics · >99 % purity
Illustrative image; appearance and packaging may vary. 10 unlabelled vials, labelled only on the kit packaging. The selected strength applies.
Research peptide
Batch analytics · >99 % purity
Illustrative image; appearance and packaging may vary. 10 unlabelled vials, labelled only on the kit packaging. The selected strength applies.
No reviews yet. Be the first to share your experience.
Research Use Only (RUO)
Tier I · Synthesis QC
Tier I · Synthesis QC
In-house · per step
RP-HPLC, MS confirmation, sequence verification in cleanroom.
Tier II · In-process
Tier II · In-process
Batch · final
Identity, purity, and assay before release.
Tier III · Third-party lab
Tier III · Third-party lab
External · independent
HPLC, ICP-MS, and microbiology by accredited lab.
953
satisfied
99.41%
Avg. purity 2026
4.8 ★
Store rating
The blend brings together two peptides that raise different questions in research. TB-500 is an acetylated fragment of thymosin beta-4 with the described sequence Ac-LKKTETQ. BPC-157 is a synthetic pentadecapeptide made of 15 amino acids. While research on BPC-157 focuses on cell movement and tendon tissue, the focus for TB-500 is on the identity of the fragment and the behavior of its metabolites.
These different perspectives make the blend interesting for peptide research. The combination brings together two substances that each represent their own experimental questions. Different peptide forms, models, and analytical questions come together. That is precisely what makes it appealing for comparative research approaches.
In preclinical regeneration research, BPC-157 is studied in connection with tendon tissue and cell movement, among other areas. The focus is on processes central to the organization of connective tissue: fibroblasts migrate into tissue, proliferate, and produce components of the extracellular matrix. For BPC-157, a study using rat tendon explants and cultured tendon fibroblasts reported enhanced outgrowth of tendon tissue, increased migration, and better survival of the cells studied (study on BPC-157 and tendon tissue).
The observed changes were accompanied by increased phosphorylation of FAK and paxillin. Both proteins are involved in controlling cell movement and cell adhesion; collagen and other matrix proteins give connective tissue its structure, while fibroblast motility and adhesion help determine how this structure forms. The finding thus links tendon tissue outgrowth with intracellular signals that support fibroblasts during migration and tissue matrix organization. The data come from rat tissue and cell cultures and are a preclinical contribution to regeneration research.
TB-500 is not full-length thymosin beta-4 but an acetylated fragment. Its sequence is described as Ac-LKKTETQ. This distinction matters because findings for the long parent protein do not automatically apply to the fragment. A study published in 2024 analyzed TB-500 and its metabolites in cell culture and rat samples (investigation of TB-500 and its metabolites).
The work separated the acetylated parent peptide from its breakdown products. In the fibroblast wound healing assay, the metabolite Ac-LKKTE showed significant activity; the parent peptide TB-500 did not reproduce this activity in the experiment. This highlights how closely peptide identity, metabolism, and observed activity are connected. For research, it is therefore crucial to know which fragment or metabolite was actually studied.
A blend brings together two different research directions: BPC-157 contributes data on fibroblast movement and tendon tissue, while TB-500 provides findings on fragment identity and metabolites. This makes the combination interesting as a research variant, because it brings two levels of peptide biology inquiry into view side by side.
The cited studies concern the components separately, not the finished blend. Statements about an additive or synergistic effect cannot be derived from them. The blend thus broadens the view of two different peptide biology profiles without conflating the individual findings.
The amount per vial is 5 mg of TB-500 and 5 mg of BPC-157. Buy TB-500 + BPC-157 now and view the blend in the shop.
Every batch is analyzed by an independent laboratory via HPLC before shipment. We document purity (avg. 99.41% in 2026), mass spectrometry identity, and sterility. Production follows GMP standards in ISO-certified laboratories.
The blend combines TB-500 and BPC-157. TB-500 is described as an acetylated fragment of thymosin beta-4, and BPC-157 as a pentadecapeptide made of 15 amino acids.
Because TB-500 covers part of the sequence of full-length thymosin beta-4. Its sequence is described as Ac-LKKTETQ.
Pentadecapeptide refers to a peptide made of 15 amino acids. The term describes the length of the peptide chain, not a specific effect.
Ac-LKKTE is a metabolite of the acetylated TB-500 parent peptide. In the cited preclinical study, the metabolite showed significant activity in the fibroblast wound healing assay.